Voice of America - March 22, 2002
Joe De Capua

Click to download/open (MP3)
Click to download/open (Real Audio)

Leading South African researchers are calling on their government to take immediate action to prevent mother-to-child transmission of HIV, the virus that causes AIDS. Writing in the British medical journal, The Lancet, they say it is the ethical and moral thing to do.

University of Natal professor Salim Abdool Karim is the lead author of The Lancet commentary. He says with over five million people in South Africa infected with HIV, “the few opportunities to control the spread of the disease need to be maximized.” Professor Abdool Salim says one of those opportunities is using drugs such as Nevirapine and AZT to protect newborns.

He says, "The government’s own estimate of 75 thousand children born with HIV infection in the year 2000 is a reasonable estimate to work with. And if we use anti-retroviral therapies, like Nevirapine and AZT, we estimate that we can close to halve that infection rate."

South African President Thabo Mbeki has questioned the safety of the drugs and says he is awaiting further research. The government is also appealing a court order that it come up a national plan to prevent mother-to-child transmission of HIV.

Despite that, a number of South African provinces have taken it upon themselves to administer the anti-retrovirals. Professor Abdool Karim says the drugs are proven to be relatively safe. "We’ve looked at the available data and we see no reason to be concerned and no reason to hold back on Nevirapine based on concerns about toxicity and drug resistance," he says.

He also rejects government arguments that breastfeeding will reduce the effectiveness of the drugs, since it is a known means of HIV transmission. He says a study done in Uganda shows breastfeeding had little impact.

"Those children." he says, "who received Nevirapine and the mothers who received Nevirapine – those children are not at increased risk of breastfeeding transmission."

As for the cost of the drugs, the University of Natal researcher says that is no longer a factor. He says, "I think there is no question about affording the drugs since the drugs are now being offered for free by the manufacturers. The issue is can we afford the infrastructure in terms of counseling and testing and the formula feeds and so on. And the answer to that is unequivocally, yes."

He says three separate studies show the benefits far outweigh the cost.

The 22 scientists who signed The Lancet commentary say it is their “moral and ethical duty to act in the best interests of their patients.” And they say there is no scientific argument to prevent them from doing so.

020322
VA020301

Copyright © 2003 - Voice of America. You are welcome to use any material that is published by voanews.com, or you may link to any of the web pages that Voice of America has published on the internet. There is no need to request further permission. Should you wish to establish a link to any VOA web pages, please send your request to pubaff@ibb.gov. We would appreciate that credit for any use of VOA material be given to voanews.com, Voice of America, or VOA, and we ask that you not abridge or edit any VOA material which you may use.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.